Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: KuDOS Pharmaceuticals Limited
• Treatments: Olaparib; Poly(ADP-ribose) Polymerase Inhibitors; Topotecan

Criteria

Inclusion Criteria:

• Histological or cytological diagnosis of advanced solid tumour for which no suitable effective therapy exists;

• Evaluable disease

• Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

• Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry; major surgery with 4 weeks of entering the study

• Heavily pre treated patient > 2 previous chemotherapy regimens for metastatic disease

• Co-existing active infection